Travere Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Travere Therapeutics Inc TVTX.OQ reported a quarterly adjusted loss of 73 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.03. The mean expectation of fifteen analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -77 cents to -47 cents per share.

• Revenue rose 66% to $74.79 million from a year ago; analysts expected $73.34 million.

• Travere Therapeutics Inc's reported EPS for the quarter was a loss of 73 cents​.

• The company reported a quarterly loss of $60.26 million.

• Travere Therapeutics Inc shares had risen by 33.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Travere Therapeutics Inc is $31.00

This summary was machine generated from LSEG data February 20 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)